{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Determine the MTD of Carfilzomib when combined with Lenalidomide and Dexamethasone. The estimated time to determine the MTD is 6 months.","groups":[{"description":"Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).\n\nLenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.\n\nDexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.","id":"OG000","title":"Carfilzomib, Lenalidomide w/Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Of the 53 patients enrolled, 35 were entered into the Phase I portion of the study.","reportingStatus":"POSTED","timeFrame":"6 Months","title":"The Maximum Tolerated Dose (MTD) of Carfilzomib","type":"PRIMARY","unitOfMeasure":"mg/m^2"}